ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.
about
Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpuraPathophysiology of thrombotic thrombocytopenic purpuraDifferent disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromesMultiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpuraVon Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpuraCurrent concepts in thrombotic thrombocytopenic purpuraPathogenesis of thrombotic microangiopathiesPulmonary tumor thrombotic microangiopathy: report of 3 cases and review of the literatureAnimal models for thrombotic thrombocytopenic purpuraThe role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpuraSuccessful pregnancy despite thrombotic thrombocytopenic purpura in the first trimesterThe von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP)Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from JapanN-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and miceThe interaction between factor H and Von Willebrand factor.A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry.Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse.Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods.Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signalling cascades.Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma.Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura.Thrombotic thrombocytopenic purpura: yesterday, today, tomorrow.Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review.Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura.FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.Thrombotic thrombocytopenic purpura and its diagnosis.The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine.The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency.Splenectomy for the treatment of thrombotic thrombocytopenic purpura.Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants.Acquired thrombotic thrombocytopenic purpura as the presenting symptom of systemic lupus erythematosus. Successful treatment with plasma exchange and immunosuppression--report of two cases.Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura.Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: reconsideration of treatment with cryopoor plasma.Thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus.Treatment of thrombotic thrombocytopenic purpura.Disseminated histoplasmosis presenting as thrombotic microangiopathy.Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation.Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.
P2860
Q24241470-716AA3BB-6C45-4354-97A8-9C36AFF772BAQ24614117-5E98DAEC-446C-4796-A59B-5C014808839BQ24616851-70123654-3AD7-4C23-9CF1-11EF49F52B1DQ24620546-F5944DAD-631B-4FFF-BCB4-EC0CE4A8AE24Q24651320-A2F362A1-DF7D-4EE7-B072-FAFBECD06899Q24656680-1B49A488-1A6F-4B43-BC55-35FA33313A94Q24658043-417E575D-05F3-4390-87F6-20B89B1809E5Q26827098-36EF6D98-3219-4FC8-83AE-336BED4A288FQ26851228-A8285F1A-999A-45B1-8185-45FAE8BB96A4Q28080631-96389364-F008-4735-9F76-8AC2BCD26329Q28200296-9C1CAFBF-CBB2-4710-815A-2404A1A30F36Q28305837-1E0AEFE2-8C8C-485B-B2B4-1B319E078A4EQ28731380-2D515B52-50A1-45E7-BA20-B125320A3A82Q30497987-5E803DA3-9494-40C8-905B-4A6F439DDE08Q31133820-BE60D235-5D6F-404C-83BB-A315E796FDCDQ33231922-0DC28036-77B9-4CD7-94DE-C25185F5C1E9Q33327295-A4C6AF82-FFB9-4228-B96F-80640DF067E1Q33349688-9DAE386C-34B3-4A0A-A4CF-D252338338FCQ33358266-D996AE36-9E89-4435-8C3C-44037F060F93Q33359551-221148AD-492E-4C46-ABC0-7B648B4DE491Q33360800-CA9786B4-9597-4710-BBC2-9A7C4576CDC1Q33361703-15AEDB93-A3AC-4F28-8688-F5AACB4564DAQ33361713-2FF949E6-4417-4B8D-9D84-8CE4A19C827BQ33361758-6FFDAB33-736C-4540-AE11-11B8C0409B01Q33363572-324100E5-E0BB-4BD1-84C8-225A8E004A68Q33365643-2765DA8B-7ADE-4E90-BAFC-B841DD5B8CA7Q33366296-697F33BB-B6A7-4F21-846E-6FAF6E777C82Q33366493-8A8B4F9A-3092-4200-89DE-7B2CB8AD8D7DQ33366935-B3E6B757-BD31-4276-8F88-1B8270D10D3EQ33368032-35FD184B-FB12-4A72-B8AA-056CBC43BD6AQ33368614-67F71CE3-5827-4179-9C47-2783C665905BQ33368709-7AF85FE7-F79D-4CFC-AD7E-7783BD4B0524Q33369692-426FA9B2-E0B1-4269-A649-E6BA3F4D348EQ33369765-0E20E84B-ABA2-4E7D-9FA9-84A06A293C27Q33369832-7B5B6237-FB4A-43D6-AC55-4EDF4AED9216Q33369985-89A5D8B9-B61B-474C-9928-9178BD5B442AQ33370956-63046BCA-E4F0-45E3-B40D-DBC430D652DEQ33371916-44E9E8F2-E25A-4183-BDA2-A219480C60E0Q33371965-AE480F18-186C-4BCC-919C-CB9CC9BCCFE0Q33372115-AC44FD29-55B7-4A48-B756-3C4117CCCE13
P2860
ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
ADAMTS13 activity in thromboti ...... ective cohort of 142 patients.
@ast
ADAMTS13 activity in thromboti ...... ective cohort of 142 patients.
@en
type
label
ADAMTS13 activity in thromboti ...... ective cohort of 142 patients.
@ast
ADAMTS13 activity in thromboti ...... ective cohort of 142 patients.
@en
prefLabel
ADAMTS13 activity in thromboti ...... ective cohort of 142 patients.
@ast
ADAMTS13 activity in thromboti ...... ective cohort of 142 patients.
@en
P2093
P50
P1433
P1476
ADAMTS13 activity in thromboti ...... ective cohort of 142 patients.
@en
P2093
Gary E Raskob
James N George
Jan-Dirk Studt
Mayez A El-Harake
P356
10.1182/BLOOD-2003-01-0193
P407
P577
2003-03-13T00:00:00Z